Tracking resistance to bedaquiline, pretomanid, and linezolid for drug-resistant TB in South Africa
Emergence of bedaquiline, pretomanid and linezolid resistance after implementation of new drug-resistant tuberculosis regimens in South Africa
This project looks at whether people with drug-resistant TB in South Africa are developing resistance to the newer drugs bedaquiline, pretomanid, and linezolid.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Columbia University Health Sciences NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11455783 on NIH RePORTER |
What this research studies
If you have drug-resistant TB in South Africa, the team will collect bacterial samples and clinical information as new oral regimens are rolled out. Laboratory testing and genetic sequencing of TB bacteria will look for mutations that make the drugs less effective. The researchers will combine lab results with treatment and transmission data to see if resistance appears locally or is spreading in the community. Findings will be used to inform treatment choices and public-health actions to limit spread.
Who could benefit from this research
Good fit: People in South Africa with multidrug-resistant or other drug-resistant TB, especially those starting or receiving bedaquiline, pretomanid, or linezolid, would be the ideal participants.
Not a fit: People with drug-susceptible TB, or those living outside South Africa and not treated with these drugs, are unlikely to benefit directly from this project.
Why it matters
Potential benefit: Could help preserve the effectiveness of new TB drugs by detecting resistance early and guiding safer treatment and public-health responses.
How similar studies have performed: Previous reports have found emerging resistance to bedaquiline and linezolid in some settings, but population-level monitoring of these newer regimens is still relatively limited.
Where this research is happening
New York, United States
- Columbia University Health Sciences — New York, United States (Active)
Researchers
- Principal investigator: Mathema, Barun — Columbia University Health Sciences
- Study coordinator: Mathema, Barun
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.